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ABSTRACT 
 
Thyroid hormone regulates essential processes in brain development such as neural cell 
migration, differentiation, signaling, and myelination, particularly during the early stages of 
gestation. During this time, fetal thyroid hormone accessibility depends on the placental transfer 
of thyroid hormones. Deficiency of thyroid hormone during fetal and postnatal periods may lead 
to permanent mental retardation and neurological deficits. Clinical studies have been conducted 
demonstrating links between maternal hypothyroidism and numerous neurodevelopmental 
disorders such as Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder, 
lower IQ, behavioral disorders, and psychiatric disorders. To investigate the effects of thyroid 
hormone actions on perinatal brain development potentially present in ASD, a literature review 
was conducted using PubMed, UCF EBSCOhost, and Google Scholar to obtain relevant papers 
for analysis. Across the board, abnormal maternal thyroid function, especially suboptimal 
maternal free thyroxine hormone, was associated with increased risk for neurological disorders, 
including ASD. The implications of this study emphasize the importance of managing maternal 
hypothyroidism during pregnancy to possibly reduce the incidence of neurodevelopmental 
disorders such as ASD.   
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INTRODUCTION 
 
Autism Spectrum Disorder (ASD) is characterized by the Center for Disease Control and 
Prevention (CDC) as a developmental disability resulting in varying levels of social, 
communicative, and behavioral disorders (1). The prevalence of ASD has skyrocketed in recent 
years, with estimates currently lying around 1 in 54 children affected with a ratio of 
approximately 4:1 boys to girls (1). Signs and symptoms can include avoiding eye contact, not 
looking at objects when someone points to them, repeating actions, appearing unaware when 
being spoken to, and failing to show interest (1, 2). Diagnosis of ASD can occur as young as 18 
months of age and with great reliability after two years of age (1). Current diagnostic criteria 
from the DSM-V focus on deficits in social interaction, nonverbal communicative patterns, and 
development and understanding of relationships (3).  
 
Characteristics of ASD Brains 
While the etiology of ASD remains unknown, numerous studies have highlighted 
deviations in neuroanatomical structures pointing towards a developmental pathology. One study 
of 277 ASD patient brains exhibiting deviation from neurotypical brains identified six areas of 
the brain with converging information in magnetic resonance images (MRI) including the lateral 
occipital lobe, the pericentral region, the medial temporal lobe, the basal ganglia, and proximate 
to the right parietal operculum (4). Multiple studies concur on the presence of abnormal 
connectivity present in ASD brains as well as alterations in grey and white matter (5, 6). Areas 
associated with social communication and repetitive behaviors such as the superior temporal 
gyrus and cingulate cortex have shown dysfunctional activation in functional MRI studies (5). 
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Potential early markers for ASD were suggested in a study analyzing the presymptomatic period 
of approximately zero to two years of age, including cortical surface area growth, increased 
volume of extra-axial cerebrospinal fluid, and abnormal white matter connectivity in the genu of 
the corpus callosum (6). This study also identifies regions of the brain prominently associated 
with the pathology of ASD, consistent with clinical presentation. These include the cerebellum, 
which functions in higher cognitive processes and language, the amygdala, which plays a role in 
emotional processing, and the frontal cortex that regulates numerous cognitive processes and 
executive brain functions such as planning, social behavior, and communication (6). Multiple 
studies confer that brain imaging within the first year of life could potentially lead to the 
prediction of ASD before visible diagnostic symptoms arise (7). 
 
Thyroid Hormones and Brain Development 
 Fetal brain development during gestation is heavily influenced by thyroid hormones 
responsible for crucial functions such as neural cell migration, differentiation, and 
synaptogenesis (8). Before midgestation, the mother is the only source of thyroxine (T4); 
therefore, adequate concentrations of maternal serum T4 for placental transfer to the fetus is 
essential for typical neurodevelopment (9).  Maternal thyroid dysfunction is strongly associated 
with poor outcomes for mother and child, such as pre-eclampsia, spontaneous abortion, 
premature birth, low birth weight, neurological cretinism, and other neurological deficits in the 
child (10, 11).  
 Given the implications of maternal thyroid hormone levels on fetal brain development, 
dysfunction of the maternal thyroid could point to the emerging etiopathological identification of 
impacted neurodevelopmental structures in ASD. The goal of this research is to conduct a 
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literature review on the association of maternal thyroid dysfunction with adverse neurological 
outcomes in the fetus that is potentially linked to ASD diagnosis as well as impacts of treating 
maternal thyroid disorders to reduce the risk of ASD.   
Thyroid hormones thyroxine (T4) and 3,5,3’-triiodothyronine (T3) are crucial for the 
development of many fetal structures, especially the central nervous system (8, 12). Upon 
entering the brain, thyroid hormones act upon class II nuclear receptors to control the expression 
of specific genes. These receptors act as a corepressor when there is no binding of the hormone, 
but upon particular hormone binding, transcription is stimulated (12). In the brain, T3 binding to 
thyroid nuclear receptor isoforms stimulates transcription of genes influencing processes, 
including myelination, cell differentiation, signaling, and migration (8, 13). The specific genes 
that thyroid hormone bind to include integrin ανβ3 membrane receptor that stimulates neocortex 
expansion, the Reln gene that influences neuronal migration in the cerebral cortex, and the Shh 
gene that controls granular cell proliferation (14).  Any conflict in these processes can lead to 
deficits in neuroontogenesis of various brain structures. For example, a study found that mutation 
of thyroid hormone receptor beta isoform leads to impairment in development of the cerebellum 
due to lack of granular cell proliferation and migration in the external granular layer (15). A 
plethora of evidence of similar detrimental effects to other neuroanatomical structures and 
functions as a result of varying levels of maternal thyroid hypofunction has been demonstrated 
including the rate of neurogenesis (16), neocortical neuronal migration (17), cortical morphology 
(18), spatial learning and synaptic nature (19), and hippocampus and memory (20). Furthermore, 
studies have pinpointed the timing of specific impairments to correspond to the period of thyroid 
hormone inadequacy during gestation (13, 21).  
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Thyroid Physiology and Placental Transfer  
 Thyroid physiology is regulated by the hypothalamic-pituitary axis. Thyroid-releasing 
hormone (TRH) is secreted by neurons in the hypothalamus and stimulates production of thyroid 
stimulating hormone (TSH) in the anterior pituitary by activating thyrotroph cells (22). TSH 
stimulates follicular cells of the thyroid to synthesize and release T3 and T4. T3 is the active 
form of the thyroid hormone but is secreted in lower quantity (20%) compared to T4 (80%) (22). 
Most T3 production results from conversion of T4 to T3 by deiodinases. In peripheral tissues like 
the liver and kidneys, T3 is converted to T4 by type 1 deiodinase while in the brain this 
conversion occurs via type 2 deiodinase produced by glial cells (23).  Both T3 and T4 in high 
levels can cause negative feedback on the anterior pituitary release of TSH, ultimately decreasing 
stimulation of T3 and T4 production (22).  
 The fetus receives thyroid hormone after maternal T3 and T4 cross the placental barrier 
during the first trimester. Research suggests that the blood-brain-barrier (BBB) is not permeable 
to the T3 form of thyroid hormone; therefore, the source of T3 in the fetal brain is the conversion 
of T4 to T3 after T4 crosses the BBB (12). Administering T4 maintains adequate physiological 
levels of T3 in the brain (12).  
 Specific transporter proteins are required for thyroid hormones to cross plasma 
membranes. Thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin (HSA) are the 
main serum proteins that bind thyroid hormone for transport (24). Transporter proteins for 
placental transfer of thyroid hormones remain up for debate. TTR is synthesized and secreted by 
placental trophoblast cells and could play a role in transport of T3 and T4 to fetus (25). Organic 
anion-transporting polypeptide, L-type amino acid, and monocarboxylate transporter are other 
5 
 
proteins identified that bind thyroid hormone for transport and are active in multiple cell types 
within the placenta (26).  
 
Thyroid Function During Pregnancy 
When a woman becomes pregnant, there is a notable change in her thyroid physiology to 
ensure adequate thyroid hormone for herself and the fetus. This change is crucial since the fetal 
thyroid does not develop enough to produce thyroid hormone until approximately the 20th week 
of gestation (10, 27). In a typical pregnancy, serum free T4 levels increase during the first and 
second trimesters through a mechanism of increased thyroid hormone binding globulin 
production in the liver due to higher estrogen levels, which increases synthesis of T3 and T4 
(27).  Serum human chorionic gonadotropin (hCG) glycoprotein is produced primarily in the first 
trimester of pregnancy by the placenta. It acts as a weak agonist to TSH, further increasing T3 
and T4 synthesis while simultaneously suppressing TSH level (27).  
 Thyroid dysfunction is relatively common in pregnancy with an estimated prevalence of 
2-4% (11). Some risk factors for thyroid dysfunction include age greater than 30 years, type I 
diabetes or other autoimmune disorder, multiple prior pregnancies, family history of thyroid 
disease, and morbid obesity (28). It is important to identify the different classifications of thyroid 
hypofunction in the context of this research. Overt hypothyroidism is characterized by low free 
T4 and high TSH concentrations with a prevalence estimated to be between 0.2-1.0% (29). 
Subclinical hypothyroidism has presence of standard free T4 with elevated TSH levels and 
represents the most common type of thyroid dysfunction in pregnancy with estimates between 
1.5-4.0% (30). Hypothyroxinemia is an isolated condition in pregnancy in which free T4 is 
below the 2.5th percentile with a normal TSH concentration (31). Differentiating these three 
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classifications of thyroid hypofunction is essential when analyzing the effectiveness of 
diagnostic techniques and possible medication suggestions.  
 Considering the importance of thyroid hormone levels for fetal nervous system 
development discussed as well as the high prevalence of maternal thyroid hypofunction, the goal 
of this research is to analyze the literature available to evaluate the potential benefits of universal 
early maternal thyroid screening. This idea paired with subsequent medical intervention to 
standardize maternal thyroid levels could possibly reduce the risk of adverse fetal outcomes such 
as ASD.  
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METHODS 
 
• To investigate effects of thyroid hormone actions on perinatal brain development 
potentially present in ASD, a literature review was conducted using PubMed, UCF 
EBSCOhost, and Google Scholar. 
• These databases were searched for articles pertaining to thyroid function on brain 
development in ASD pregnancy by inputting keywords such as: Autism, thyroid function, 
pregnancy, maternal, hypothyroidism, hypothyroxinemia, brain development, 
levothyroxine.  
• Articles containing selected key words were analyzed and selected based on relevance. 
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MATERNAL THYROID HYPOFUNCTION AND ASD DIAGNOSIS 
RATES 
 
 Numerous case-cohort studies have been conducted analyzing maternal thyroid 
hypofunctions of varying severity and subsequent diagnoses of neurological disorders in the 
child, especially involving ASD.  
Levie et al. conducted a meta-analysis to assess impacts of low maternal free T4 levels 
during early pregnancy (less than 18 weeks) on IQ and autistic traits. They concluded that low 
maternal free T4 was associated with lower verbal and nonverbal IQ across all cohorts, 
hypothyroxinemia has a possible association with autistic traits, and confirmed the reliability of 
free T4 as an indicator of the fetal thyroid state (32).  
A case-cohort study assessed free T4 and thyrotropin level at week 9 of pregnancy and 
subsequent diagnoses of neurodevelopmental disorders including seizures, ASD, and ADHD in 
the children. Abnormal maternal thyroid function was most prevalent in the ASD cases 
compared to the other disorders. Maternal overt hypothyroidism presented the most risk factors 
for ASD (33). This research group produced a follow-up study that reassessed the 
neuropsychological performance of the children at age five years and reaffirmed that maternal 
thyroid dysfunction caused deficits in neurological development. Additionally, after performing 
intelligence and function tests, the researchers were able to draw further conclusions that 
maternal overt hypothyroidism had a greater effect on intelligence in the child while maternal 
hypothyroxinemia mainly affected motor and executive functions as well as behavior problems 
(34).  
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A retrospective cohort study showed that women diagnosed with hypothyroidism both 
before and during pregnancy had children with higher rates of ASD diagnosis. The association 
was seen in ASD diagnosis in both boy and girl children (35). Fetene et al. conducted a 
systematic review regarding maternal thyroid dysfunction and neurological disorders in the child 
and concluded that particularly maternal overt hypothyroidism displayed the highest rates of 
behavior and psychiatric disorders including ASD (36).  
 
A Focus on Hypothyroxinemia  
Another case-cohort study found an association between women with severe 
hypothyroxinemia (free T4 < 5th percentile and normal TSH) and a four-fold increased risk of 
having a child with probable ASD based on a Pervasive Developmental Problem subscale (37). 
Thompson et al. conducted a large scale meta-analysis of 39 studies showing association of 
maternal hypothyroxinemia and subclinical hypothyroidism with intellectual disabilities and 
neurodevelopmental disorders in children (38).  
A 3-year follow-up study after collection of maternal free T4 levels at 12 weeks of 
gestation demonstrated that maternal hypothyroxinemia leads to a higher rate of deficits in 
mental and motor function in children. This study also showed that an increase to standard levels 
of free T4 in women with hypothyroxinemia in weeks 24-32 of gestation did not have better fetal 
outcomes (39). This data reflects the crucial function of thyroid hormone in early gestation for 
fetal brain development before the fetus is able to synthesize T3 and T4 independently. 
Similarly, Kooistra et al. assessed neurobehavioral function of infants born to mothers with 
maternal hypothyroxinemia at 12 weeks gestation. Neonates of women with low free T4 levels in 
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early pregnancy scored significantly lower on the Neonatal Behavior Assessment Scale which 
assesses motor behavior, response to stress, adaptive behavior, and state organization at 3 weeks 
of age. The results also established that only first-trimester maternal hypothyroxinemia acted as a 
predicting factor for the assessment score, once more aligning with the timeline of fetal 
neurodevelopment (40).  
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CLINICAL INTERVENTIONS FOR MATERNAL THYROID 
HYPOFUNCTION AND FETAL OUTCOMES 
 
Considering the well-documented adverse maternal and fetal outcomes of various levels 
of maternal thyroid hypofunction including pre-eclampsia, spontaneous abortion, premature 
birth, low birth weight, neurological cretinism, and other neurological deficits (10, 11), clinical 
interventions for affected women planning pregnancy is encouraged.  
 Treatment options for hypothyroidism primarily include synthetic hormone replacement. 
Synthetic T4, levothyroxine (LT4), is the most common medication administered to patients with 
low T4 levels (41). LT4 and liothyronine (synthetic T3) combination therapies have also been 
developed; however, recent research confers that LT4 should remain standard of care for 
suboptimal thyroid hormone levels including hypothyroxinemia as clinical studies have shown 
inconclusive results that LT4-liothryonine combination therapies are superior to LT4 
monotherapy (42, 43).  
Duntas and Jonklaas identified factors that may require adjustment of a patient’s LT4 
dose including weight and hormonal changes, aging, and pregnancy citing that up to 85% of 
pregnant women require an increase of their LT4 dose (44). The 2017 Guidelines of the 
American Thyroid Association for the Diagnosis and Management of Thyroid Disease During 
Pregnancy and the Postpartum recommends LT4 treatment for women with overt 
hypothyroidism and encourages consideration of LT4 treatment for women with subclinical 
hypothyroidism to avoid possible progression of hypothyroidism upon becoming pregnant. The 
guidelines emphasize monitoring of TSH levels every 4 weeks and encourage LT4 treatment 
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when TSH is above 2.5 mU/L. It is recommended that women receiving LT4 treatment for 
hypothyroidism increase their dose by 20-30% upon confirmation of pregnancy (45).  
 
Case Studies: Levothyroxine Treatment During Pregnancy 
Case studies analyzing maternal and fetal outcomes when the mother is treated with LT4 
during pregnancy are in relative abundance. The Thyroid Hormone Early Adjustment in 
Pregnancy (THERAPY) trial concluded that increasing LT4 dose by two tablets upon 
confirmation of pregnancy successfully mirrors typical pregnancy physiology and reduces 
hypothyroidism in the mother in the first trimester (46).  
 A 2019 meta-analysis conducted supports the benefits of LT4 medication in women with 
subclinical hypothyroidism during pregnancy citing lower risk of miscarriage and preterm birth 
(47). Meta-analyses of randomized controlled trials also show evidence for higher delivery rates 
and lower miscarriage rates with LT4 supplementation during pregancy. These studies have also 
demonstrated reduced gestational diabetes and hypertension in mothers, higher birth weights, 
and fewer congenital malformations with LT4 intervention (48, 49).  
 One clinical study analyzed the effects of LT4 supplementation in pregnant women with 
subclinical hypothyroidism compared to pregnant women with hypothyroxinemia. The 
significant findings were reduced premature birth and low birth rate risks in both groups and 
additionally decreased gestational hypertension in the subclinical hypothyroidism group (50).  
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 Clinical research regarding LT4 intervention for maternal hypofunction during pregnancy 
and subsequent analysis of neurological outcomes in the fetus is few and far between. The results 
tend to not support the hypothesis of this research.  
 Casey et al., found that women treated for subclinical hypothyroidism and 
hypothyroxinemia at means of 16.7 and 17.8 weeks of gestation respectively did not have 
children with significantly better neurocognitive outcomes than untreated women (51). Another 
study analyzed randomized controlled trials and found lacking data for evidence of less risk for 
neurosensory disability in the child after the mother was treated with LT4 for thyroid 
hypofunction. One trial included women screened before 11 weeks gestation and the other trial 
included women screened before 15 weeks gestation (52). A solo randomized control trial 
analyzed children at 3 years of age and did not find improvement in cognitive function in 
children born to mothers treated for hypothyroidism at 12 weeks 3 days median gestation (53). 
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DISCUSSION 
 
Implications  
 
Gaps in the Research 
 While conducting this literature review, it became apparent that a gap in the research 
exists in assessing the effectiveness of LT4 treatment for maternal hypofunction and subsequent 
neurological outcomes, ASD traits, and ASD diagnosis of offspring. A multitude of studies 
suggest that adverse maternal and fetal outcomes such as pre-eclampsia, gestational diabetes and 
hypertension, early delivery, miscarriage, low birth weight, and congenital malformations are 
reduced by adequate LT4 intervention (44-50). The few studies that do include assessment of 
neurological outcomes in children only consider IQ scores as a comparison benchmark to the 
control individuals (51-53). In order to better understand the possibility of reducing ASD in 
children with LT4 treatment for hypothyroid mothers, researchers should conduct studies 
including more in depth neurological follow-up including ASD diagnosis as well as evaluation of 
ASD traits such as social, communicative, and behavioral deficits.  
 
Timing of LT4 Treatment  
A crucial factor to consider when analyzing the effects of LT4 intervention on neurological 
outcomes is the gestational age of the embryo or fetus when the treatment begins. The mother is 
the only source of thyroid hormone for the fetus up to midway through the pregnancy (9). Key 
neurological structures and begin their development as early as week three of gestation 
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including: medulla, pons, cerebellum, thalamus, hypothalamus, amygdala, neocortex, and 
hippocampus (50, 51). Additionally, essential brain functions synaptogenesis, myelinogenesis, 
and gliogenesis occur in the fetus as early as week five (54, 55).  
The current clinical studies analyzing the effect of LT4 treatment during pregnancy on 
fetal neurodevelopmental outcomes show concerning gestational age for the start of the 
treatments. The studies averaged a median gestation ranging from 12-18 weeks as the starting 
point for implementation of thyroxine replacement (51-53). Other studies have demonstrated that 
the specific time of insufficient thyroid hormone during gestation corresponds to deficits in the 
typical development at the same point in time (13, 21). This creates questions about the efficacy 
of LT4 supplementation on nervous system development after the first trimester.  
 
Necessity for Universal Early Thyroid Screening  
 
 It is evident that adequate thyroid hormone levels are necessary to ensure a typical 
development of numerous vital organs, especially in the central nervous system. For this reason, 
debates on the application of universal thyroid screening has been an emerging topic in prenatal 
care as well as for those trying to conceive. Current protocol used by most healthcare providers 
only seeks to target pregnant women with overt hypothyroidism (56). An analysis of cost-
effectiveness of universal screening for subclinical hypothyroidism in pregnancy found that 
universal screening of all pregnant women is cost-effective in both financial as well as quality of 
life considerations (57). Taylor et al. highlight the importance to recruit women pre-conception 
for clinical studies to further confirm the efficacy of immediate T4 replacement as necessary 
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(53).  For this reason, many researchers and clinicians are now urging the universality of thyroid 
screening to prevent neurological malformations (58-60). 
  Universal thyroid screening could allow the execution of effective and timely treatment 
for overt and subclinical levels of maternal thyroid hypofunction that could show promise in 
ameliorating risk for adverse neurological outcomes in the fetus, especially the risk of ASD.  
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